I Engelbrecht Research Pty, Ltd

Lyttelton, Gauteng 0157

0 studies enrolling now · 3 studies all time

What they study most

Cardiovascular Disease, Smoking Cessation

Studies at this site

• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders — Completed